Medicine

Brain Stimulation Boosts Thinking Skills in Parkinson’s Patients

How the science connects

Parkinson's diseaseCognitive impairmentDeep brain stimula…

AI Insight

This pilot study tested a novel deep brain stimulation approach in five Parkinson's disease patients with cognitive impairment, combining continuous stimulation of the subthalamic nucleus for motor symptoms with intermittent stimulation of the nucleus basalis of Meynert for cognitive symptoms. After six months, all five participants showed clinically meaningful cognitive improvements alongside expected motor benefits, with successful electrode placement achieved through either vertical or lateral surgical approaches. The automated programming system allowed safe delivery of intermittent stimulation without adverse effects.


Cognitive decline in Parkinson's disease currently has limited treatment options, and this technique demonstrates that targeting the brain's cholinergic system through intermittent deep brain stimulation may address both motor and cognitive symptoms simultaneously. If validated in larger trials, this could provide a meaningful therapeutic option for Parkinson's patients experiencing cognitive impairment.


Understand the Science

Parkinson's disease 33 articles Explore Concept → Cognitive impairment Concept coming soon Deep brain stimulation Concept coming soon

⚠️ Preprint – Noch nicht peer-reviewed

Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.

Cognitive decline begins in early stages of Parkinson’s disease (PD) for many individuals and remains largely untreated. The nucleus basalis of Meynert (NBM), the brain’s cortical cholinergic hub, and its lateral efferent fiber bundle degenerate early in PD and are linked to cognitive and cognitive-motor impairment. Pre-clinical evidence indicates intermittent stimulation of the NBM improves cognition. The objective of this study is to establish the feasibility of combined continuous subthalamic nucleus (STN) and intermittent NBM DBS for cognitive impairment in people with PD. Five patients with PD and cognitive impairment approved for STN DBS were enrolled as part of an ongoing clinical trial for combined STN and NBM DBS under an Investigational Device Exemption. Three participants received a ‘vertical’ trajectory in which two leads were placed in the STN, and two additional leads were placed in the anterior portion of the NBM, both using the same burr hole for each hemisphere. The two other participants received a novel ‘lateral trajectory’ in which the NBM leads were placed along the NBM lateral efferent bundle via a small twist craniostomy behind the ear. An automated programming algorithm DBS Illumina 3D (Boston Scientific) was used to program the NBM leads based on volume of tissue activated modeling. The investigational Chronos software (Boston Scientific) was used to deliver continuous high frequency DBS to the STN 24 hours/day and intermittent patterned DBS to the NBM for 1 hour/day. The two leads placed in the NBM (‘Vertical’ target) or its lateral efferent bundle (‘Lateral’ target) were successfully and accurately placed as part of the usual STN DBS procedure. All participants were successfully programmed using the Illumina 3D algorithm without adverse effects. Following 6 months of combined continuous STN and intermittent NBM DBS, all five participants saw clinically meaningful improvements in cognition as part of a neuropsychological assessment battery, as well as the expected motoric benefit from STN DBS. The current study demonstrated that intermittent stimulation of the NBM to target cortical cholinergic deficits may provide clinically meaningful improvements in cognitive symptoms in Parkinson’s disease.

Source: Clinically Meaningful Cognitive Improvement from Intermittent Neurostimulation of the Nucleus Basalis of Meynert in Parkinson's Disease